Achilles Therapeutics Plc - ADR Stock

$1.07

0.94% yesterday

Nasdaq, Nov 25, 10:00 pm CET

ISIN

US00449L1026

Symbol

ACHL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Achilles Therapeutics Plc - ADR Stock price

$1.07

-15.48 93.53% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

+0.01 0.94%

ISIN

US00449L1026

Symbol

ACHL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$43.98m
Enterprise Value	$-38.45m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	0.60
P/B ratio (TTM) P/B ratio	0.43
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-72.42m
Free Cash Flow (TTM) Free Cash Flow	$-64.33m
Cash position	$86.05m
P/E forward	negative
Short interest	0.63%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Achilles Therapeutics Plc - ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Achilles Therapeutics Plc - ADR:

1x Hold

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Achilles Therapeutics Plc - ADR:

Hold

100%

Analyst Estimates with Stock Price Targets

Financial data from Achilles Therapeutics Plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	4.73 4.73	42% 42% -
Gross Profit	-4.73 -4.73	- -
- Selling and Administrative Expenses	6.59 6.59	53% 53% -
- Research and Development Expense	56 56	3% 3% -
EBITDA	-68 -68	- -
- Depreciation and Amortization	4.73 4.73	- -
EBIT (Operating Income) EBIT	-72 -72	0% 0% -
Net Profit	-67 -67	11% 11% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Achilles Therapeutics Plc - ADR Stock News

Neutral

GlobeNewsWire

●

7 days ago

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is exp...

Neutral

GlobeNewsWire

●

12 days ago

Achilles Therapeutics Reports Third Quarter 2024 Financial Results

– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –

Neutral

GlobeNewsWire

●

2 months ago

Achilles Therapeutics Announces Strategic Update

–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice– LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical ...

More Achilles Therapeutics Plc - ADR News

Company Profile

Achilles Therapeutics Plc is a biopharmaceutical company engages in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Iraj Ali
Employees	215
Founded	2016
Website	www.achillestx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now